Effectiveness of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in a Novel Model for Compartmentalized Neuroinflammation in Multiple Sclerosis

被引：0
|
作者：
Kebir, H. [1 ]
Li, C. [1 ]
May, M. J. [2 ]
Church, M. E. [1 ]
Boschert, U. [3 ]
Alvarez, J. I. [1 ]
机构：
[1] Univ Penn, Pathobiol, Philadelphia, PA 19104 USA
[2] Univ Penn, Biomed Sci, Philadelphia, PA 19104 USA
[3] Merck KGaA, Ares Trading SA, Aubonne, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
CE1.3
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [1] Evobrutinib, a Bruton's tyrosine kinase inhibitor, acts on microglia: implications in treatment of progressive multiple sclerosis mechanisms
    Geladaris, A.
    Torke, S.
    Haselmayer, P.
    Boschert, U.
    Bruck, W.
    Weber, M. S.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 609 - 609
  • [2] The Bruton's Tyrosine Kinase Inhibitor Evobrutinib Demonstrates Superior Efficacy in Targeting Compartmentalized Neuroinflammation Compared to Anti-CD20 Treatment
    Kebir, H.
    Li, C.
    May, M. J.
    Church, M. E.
    Boschert, U.
    Alvarez, J. I.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 88 - 88
  • [3] The Bruton's Tyrosine Kinase Inhibitor Evobrutinib Demonstrates Superior Efficacy in Targeting Compartmentalized Neuroinflammation Compared to Anti-CD20 Treatment
    Kebir, Hania
    Li, Cen
    May, Michael
    Church, Molly
    Shafaatian, Ursula Boschert
    Alvarez, Jorge
    NEUROLOGY, 2023, 100 (17)
  • [4] Evobrutinib, a Bruton′s tyrosine kinase inhibitor, modulates microglia activity in vivo
    Geladaris, A.
    Torke, S.
    Haselmayer, P.
    Boschert, U.
    Brueck, W.
    Weber, M. S.
    GLIA, 2023, 71 : E946 - E946
  • [5] Brain-homing B cells in multiple sclerosis: association with Bruton's tyrosine kinase and targeting by evobrutinib
    Rijvers, Liza
    Melief, Marie-Jose
    van Langelaar, Jamie
    Hendriks, Rudi
    Boschert, Ursula
    Grenningloh, Roland
    Smolders, Joost
    van Luijn, Marvin
    NEUROLOGY, 2021, 96 (15)
  • [6] Immune response following mRNA COVID-19 vaccination in patients with multiple sclerosis treated with the Bruton's tyrosine kinase inhibitor evobrutinib
    Bar-Or, A.
    Cross, A. H.
    Cunningham, A.
    Hyvert, Y.
    Seitzinger, A.
    Drouin, E. E.
    Alexandri, N.
    Tomic, D.
    Montalban, X.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 962 - 963
  • [7] Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor
    Bar-Or, Amit
    Cross, Anne H.
    Cunningham, Anthony L.
    Hyvert, Yann
    Seitzinger, Andrea
    Guehring, Hans
    Drouin, Elise E.
    Alexandri, Nektaria
    Tomic, Davorka
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (11-12) : 1471 - 1481
  • [8] Effects of evobrutinib, a Bruton's tyrosine kinase inhibitor, on slowly expanding lesions: an emerging imaging marker of chronic tissue loss in multiple sclerosis
    Arnold, D.
    Elliott, C.
    Montalban, X.
    Martin, E.
    Hyvert, Y.
    Tomic, D.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 69 - 69
  • [9] Safety of the bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis during an open-label extension to a phase ii study
    Montalban, X.
    Arnold, D. L.
    Weber, M.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Martin, E.
    Mandel, M.
    Ona, V.
    Zima, Y.
    Tomic, D.
    Wolinsky, J.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 233 - 233
  • [10] Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis
    Schneider, Raphael
    Oh, Jiwon
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2022, 22 (11) : 721 - 734
12345